Results 241 to 250 of about 2,610,317 (379)
IL-1β alters the virulence of uropathogenic Escherichia coli. [PDF]
Kalaycı-Yüksek F +3 more
europepmc +1 more source
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Association of IL-1β rs16944 polymorphisms and the subsequent level of IL-1β in type 2 diabetes mellitus: Case-control study. [PDF]
Khdaer HM +11 more
europepmc +1 more source
IL-1β-Mediated Innate Immunity Is Amplified in the db/db Mouse Model of Type 2 Diabetes [PDF]
Jason C. O’Connor +7 more
openalex +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source
Design and Synthesis of Novel Purine Analogues as Potential IL-1β Inhibitors Targeting Vascular Inflammation. [PDF]
Pournara DT +6 more
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source

